Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384151 | 0.84 | HRH1 (0.46) | KDM4EALDH1A1SMN1; SMN2HRH1DRD2 | |
| SCHEMBL19384157 | 0.81 | HTR1D (0.58) | HRH1DRD2DRD1DRD4DRD5 | |
| SCHEMBL3470698 | 0.81 | SMN1; SMN2 (0.49) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL25388128 | 0.76 | HTR7 (0.66) | KDM4EALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2936654 | 0.75 | L3MBTL1 (0.59) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL7030837 | 0.75 | MEN1 (0.46) | KDM4EALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL22551906 | 0.75 | ALDH1A1 (0.42) | KDM4EALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL7781498 | 0.75 | L3MBTL1 (0.47) | KDM4EALDH1A1HRH1DRD2DRD1 | |
| SCHEMBL28086775 | 0.74 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2HRH1DRD2 | |
| SCHEMBL9570663 | 0.74 | L3MBTL1 (0.42) | KDM4EALDH1A1SMN1; SMN2HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100498-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2019-04-04 | — | — | US | disclosed |
| EP-3433237-A1 | CRYSTALLINE FORM | Astrazeneca AB (SE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100498-A1 | CRYSTALLINE FORM | GYS2, PYGL, SFPQ | KDM4E 4682/4885ALDH1A1 1587/4885SMN1; SMN2 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.